Asia appears to be global center for counterfeit, substandard drugs

06/16/2013 | Economic Times (India), The

Asia, particularly China and India, appears to be the chief source of what the World Health Organization now labels "substandard, spurious, falsely labelled, falsified and counterfeit (SSFFC) medicines." The global market for such fake drugs could be in the range of $50 billion to $200 billion, according to several reports, although authorities point out that large pharmaceutical firms, with export markets and reputations to protect, are rarely the problem.

View Full Article in:

Economic Times (India), The

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Consumer Directed Health Plan (CDH) Product Offering Manager
Blue Cross Blue Shield MA
Quincy, MA
ISHN - Chief Compliance Officer
Mountain States Health Alliance
Johnson City, TN
Actuary
Meridian Health Plan
Detroit, MI
President/Chief Executive Officer
MedCost
Winston-Salem, NC
Director, Payer Marketing
Avalere Health
Washington, DC